To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

CarMollNat Muscular Dystrophy Endowment
Biomarkers Consortium - Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s Plasma Abeta project will evaluate next generation plasma Aβ assays to determine whether plasma Aβ peptide ratios increase the probability of identifying patients with amyloid positivity to improve clinical trial screening efficiency and reduce clinical trial costs for early stages of Alzheimer’s Disease.

Gene Drive Research-Related Activities

Gene drive is a mechanism that can promote the preferential inheritance of a beneficial genetic trait, thereby increasing its prevalence in a population. A variety of gene drive mechanisms occur in nature that can cause specific genetic elements to spread throughout populations in varying degrees. Researchers have long sought to harness these naturally occurring gene drive mechanisms to prevent the transmission of mosquito or other insect-borne diseases that pose some of society's most intractable public health problems.

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

Accelerating Medicines Partnership - Alzheimer's Disease

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. 

Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED)

The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is a landmark study that has profoundly influenced our understanding of Alzheimer’s disease by identifying the earliest changes in brain structure and function that signal its onset and progression.

Global Health Fund

The Global Health Fund supports FNIH programs that are designed to alleviate widespread suffering in the developing world. Program focus includes research and training on diseases such as malaria and HIV, as well as conditions like malnutrition that afflict hundreds of millions of people globally.

Alzheimer's Disease Neuroimaging Initiative 2

ADNI was established to facilitate the development of effective treatments for Alzheimer’s disease by validating biomarkers for clinical trials and determining the relationships between the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of AD.  

Biomarkers Consortium - Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders

This project will aim to standardize and validate measurement methods for inflammatory markers associated with Alzheimer’s Disease and/or Major Depressive Disorder to ultimately identify a unique biosignature of disease. The identified biosignature would greatly assist with medication development, patient diagnosing, and patient selection for clinical trials.